.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The IMS-IMWG 2025 staging system provides a vital tool for managing newly diagnosed multiple myeloma (NDMM). This model integrates genomic data to define high-risk (HR) subsets accurately. Furthermore, clinicians now use this system to improve consistency in clinical trial reporting. Researchers recently validated these criteria in patients receiving daratumumab-based quadruplet therapy.
Specifically, a study analyzed 503 NDMM patients at Memorial Sloan Kettering Cancer Center. These patients underwent induction with anti-CD38 monoclonal antibody quadruplets. Consequently, findings showed that the new definition delineates risk better than legacy scores. Notably, the criteria identified 31% of patients as high-risk.
Although modern therapy is potent, survival differences remain significant. Interestingly, the IMS-IMWG 2025 staging did not predict early minimal-residual disease (MRD) negativity. HR and standard-risk (SR) patients reached MRD negativity at nearly identical rates. However, the genomic staging strongly predicted long-term survival outcomes.
Specifically, HR patients had a median progression-free survival (PFS) of only 2.6 years. In contrast, the median PFS for SR patients was not reached (p < 0.001). Moreover, the model predicted overall survival (OS) with high statistical significance (p = 0.003). Therefore, this staging system is essential for identifying patients who require closer monitoring or novel interventions.
It is the first to include TP53 mutations and specific co-occurrences of IgH translocations with chromosome 1 aberrations.
Yes, the study demonstrated that the genomic criteria effectively predict both progression-free survival and overall survival.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Maclachlan KH et al. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Feb 17. doi: undefined. PMID: 41701976.
Avet-Loiseau H, et al. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43(24):2739-2751.
International Myeloma Foundation. IMS-IMWG Consensus Definition of HRMM. June 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The new IMS-IMWG 2025 consensus genomic staging effectively predicts survival in NDMM patients treated with daratumumab-based quadruplet regimens....
6 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
